rasagiline has been researched along with Depressive Disorder in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, T; Minami, A; Muraoka, S; Okano, M; Satoyoshi, H; Takahata, K; Tsukamoto, Y; Tsunekawa, H | 1 |
| Bakhle, YS; Youdim, MB | 1 |
1 review(s) available for rasagiline and Depressive Disorder
| Article | Year |
|---|---|
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Topics: Animals; Cholinesterase Inhibitors; Dementia; Depressive Disorder; History, 20th Century; History, 21st Century; Humans; Indans; Iron; Iron Deficiencies; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline | 2006 |
1 other study(ies) available for rasagiline and Depressive Disorder
| Article | Year |
|---|---|
Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Topics: Animals; Antidepressive Agents; Corticosterone; Depressive Disorder; Dopamine; Dose-Response Relationship, Drug; Hippocampus; Indans; Male; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuronal Plasticity; Prefrontal Cortex; Rats, Wistar; Selegiline; Synaptic Transmission; Time Factors | 2019 |